NVS Jan 2024 100.000 put
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 11:20AM EST. Market open.
Loading interactive chart…
- Zacks
Novartis (NVS) Raises Mid-Term Sales Outlook; Outlines Strategy
Novartis (NVS) increases its sales guidance for the mid-term (2022-2027) and outlines its growth strategy as a pure-play pharmaceutical company.
- Financial Times
Novartis: CEO needs to convince over long-term prospects
It is tempting to celebrate big milestones. Novartis chief Vas Narasimhan can be forgiven for doing so. His focus is on higher-margin, innovative drugs. The Swiss group is a cleaner proposition after spinning off its generics business Sandoz in October.
- Zacks
3 Large Drug Stocks That Have Outperformed Industry YTD
Eli Lilly (LLY), Novo Nordisk (NVO) and Novartis (NVS) have outperformed the industry this year.
© 2023 Yahoo. All rights reserved.